All In Biotech

Drug Trial Radar · NCT03547973

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

502

Actual

Start

Aug 13, 2018

Primary completion

Apr 2030

Study completion Apr 2030

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Jun 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).

Conditions

  • Metastatic Urothelial Cancer

Interventions

  • Sacituzumab Govitecan-hziyDrug

    Administered intravenously.

  • PembrolizumabDrug

    Administered per package insert

  • CisplatinDrug

    Administered per package insert

  • AvelumabDrug

    Administered per package insert

  • ZimberelimabDrug

    Administered intravenously

  • CarboplatinDrug

    Administered per package insert

  • GemcitabineDrug

    Administered per package insert

  • DomvanalimabDrug

    Administered intravenously

  • Enfortumab VedotinDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) Based on Central Review by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Criteria (Cohorts 1 to 4 and 6)Time frame: Up to Survival Follow-up Visit (maximum of 2 years after Safety Follow-up Visit (30 days after last dose date))
  2. Progression free survival (PFS) Based on Central Review by RECIST 1.1 criteria (Cohort 5)Time frame: Up to Survival Follow-up Visit (maximum of 2 years after Safety Follow-up Visit (30 days after last dose date))
  3. ORR Based on Investigator Review by RECIST 1.1 Criteria (Cohort 7)Time frame: Up to Survival Follow-up Visit (maximum of 2 years after Safety Follow-up Visit (30 days after last dose date))
  4. Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) (Cohort 7)Time frame: First dose date up to last dose date plus 30 days (approximately 3 years)
  5. Percentage of Participants Experiencing any Clinically Significant Laboratory Abnormalities (Cohort 7)Time frame: First dose date up to last dose date plus 30 days (approximately 3 years)

Locations

128 sites in 9 countries. Site status is shown where the registry gives one.

  • The University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • University of California San Francisco

    San Francisco, California

  • Rocky Mountain Cancer Centers

    Littleton, Colorado

  • Smilow Cancer Hospital at Yale-New Haven

    New Haven, Connecticut

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • Woodlands Medical Specialists, PA

    Pensacola, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • University of Illinois Cancer Center

    Chicago, Illinois

  • University of Chicago Medical Center

    Chicago, Illinois

  • Southern Illinois University School of Medicine, Simmons Cancer Institute

    Springfield, Illinois

  • Norton Cancer Institute, Downtown

    Louisville, Kentucky

  • University of Michigan

    Ann Arbor, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Precision Cancer Research / New Mexico Oncology & Hematology Consultants

    Albuquerque, New Mexico

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York

  • Drug Shipping Address: New York-Presbyterian Hospital

    New York, New York

  • Stony Brook Cancer Center

    Stony Brook, New York

  • St. Luke's Hosptial - Bethlehem Campus

    Easton, Pennsylvania

  • Medical University of Southern Carolina

    Charleston, South Carolina

  • Thompson Oncology Group - Knoxville West

    Knoxville, Tennessee

  • Henry-Joyce Cancer Clinic

    Nashville, Tennessee

  • Houston Methodist Hospital, Houston Methodist Cancer Center

    Houston, Texas

  • Mays Cancer Center

    San Antonio, Texas

  • University of Utah - Huntsman Cancer Hospital (IP Shipping Address)

    Salt Lake City, Utah

  • Virginia Oncology Associates

    Hampton, Virginia

  • Oncology Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

    Roanoke, Virginia

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • University of Wisconsin Clinical Science Center

    Madison, Wisconsin

  • Centre Hospitalier Regional Universitaire (CHRU) de Besancon, Hopital Jean Minjoz

    Besançon, France

  • Hopital Saint Andre (CHU de Bordeaux)

    Bordeaux, France

  • Centre Hospitalier Regional Universitaire Brest

    Brest, France

  • Centre Jean Perrin

    Clermont-Ferrand, France

  • Centre Hospitalier Departmental (CHD) Vendee

    La Roche-sur-Yon, France

  • Centre Oscar Lambret

    Lille, France

  • Centre Leon Berard

    Lyon, France

  • Institut Paoli Calmettes

    Marseille, France

  • Centre Antoine Lacassagne

    Nice, France

  • Centre Hospitalier Universitaire De Nimes - Hopital Universitaire Caremeau

    Nîmes, France

Showing 40 of 128 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.